Clinical Trials Directory

Trials / Completed

CompletedNCT05115305

Prodigy, a Level 2 Sleep Study Device, Validation Study

Validation of a Level 2 Sleep Study Device

Status
Completed
Phase
Study type
Observational
Enrollment
84 (actual)
Sponsor
Cerebra Medical · Industry
Sex
All
Age
18 Years
Healthy volunteers

Summary

The Prodigy system, developed by Cerebra Medical Ltd, allows for the generation of the same information in the home that is currently only obtained in in-laboratory studies. The objective of the current study is to demonstrate that the signals obtained by this comprehensive, portable system are comparable to those obtained in in-laboratory studies.

Detailed description

This study consists of obtaining standard polysomnography signals concurrently by the Prodigy 2 and by the standard commercial systems used in the Sleep Disorders Clinic (Alice G3) in Hamilton, ON and the St. Charles Sleep Disorders Center (Nihon Kohden) in Port Jefferson, NY. 42 patients will be recruited from each of the two sites, for a total of 84 patients. Questionnaires on demographics and mental health, including the Depression Anxiety Stress Scale-21, questionnaires on sleep and fatigue including Pittsburgh Sleep Quality Index, Insomnia Severity Index, and Epworth Sleepiness Scale and questionnaires on quality of life including the Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10) and the Euroquol 5D-5L will be completed online using a survey platform (Qualtrics or RedCap).

Conditions

Timeline

Start date
2022-01-14
Primary completion
2022-04-09
Completion
2022-04-09
First posted
2021-11-10
Last updated
2022-07-20

Locations

2 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT05115305. Inclusion in this directory is not an endorsement.

Prodigy, a Level 2 Sleep Study Device, Validation Study (NCT05115305) · Clinical Trials Directory